A2Z Cust2Mate Solutions Corp. (AZ) Reports Q2 Loss, Beats Revenue Estimates

A2Z Cust2Mate Solutions Corp. (AZ) reported Q2 adjusted EPS loss of $0.16, matching the Zacks Consensus Estimate, versus a $0.31 loss a year earlier. Revenue rose to $5.9M for the quarter ended June 2026, beating consensus by 73.65% and up from $1.16M a year ago. Consensus for next quarter is -$0.09 EPS on $8.7M revenue.

Original reporting
Published Aug 12, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AZ
Neutral
medium confidence
Mentioned
$AZ
Relevance
6/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$AZNeutralMed
01

Why it matters

Q2 shows a large revenue beat but continued adjusted EPS losses, so the key trading variable is whether management commentary shifts near-term EPS expectations and estimate revisions from the current mixed trend.

02

Market read

This is a company-specific earnings update with a revenue upside but no EPS improvement, making the next catalyst the earnings call and any subsequent estimate revisions.

03

What to watch

The article notes mixed estimate revisions and a Hold (Zacks Rank #3); traders should focus on whether the earnings call changes the coming-quarter and FY consensus trajectory.

Relevance 6/10Novelty 6/10Timing: after-hours/next-session reaction to newly released Q2 results and earnings-call commentary

Background

The piece summarizes A2Z Cust2Mate Solutions’ Q2 results versus consensus and discusses the earnings-outlook framework (estimate revisions, Zacks Rank).

Company-level read

Ticker impact

$AZNeutralMedium confidence
Context

A2Z Cust2Mate Solutions reported Q2 adjusted EPS of -$0.16 and revenues of $5.9M, beating revenue estimates by 73.65%.

Expected impact

Likely choppy/mean-reverting unless the earnings call meaningfully changes near-term EPS and revenue outlook.

Evidence & confidence

The article provides hard Q2 results (EPS in line, revenue beat) but no new guidance numbers; it flags that stock follow-through depends on management commentary and upcoming estimate revisions.

Market effects

Limited direct read-through, but reinforces that small-cap internet/software names can see revenue volatility without EPS inflection.

No specific regional spillover described.

No global macro or cross-border catalyst mentioned.

Counterpoint

Revenue beat may not translate into durable profitability if losses persist and future consensus remains negative.

Key entities

  • A2Z Cust2Mate Solutions Corp.

    Reported Q2 adjusted EPS of -$0.16 and revenues of $5.9M, with revenue beating consensus by 73.65%.

  • Zacks Consensus Estimate

    Used as the comparison point for EPS and revenue beats/misses in the article.

  • Zacks Rank #3 (Hold)

    The article states the stock is expected to perform in line with the market near term based on the current rank.

Related articles

$AZMed

A2Z CUST2MATE SOLUTIONS CORP. (AZ): Financial results for FY2025

A2Z CUST2MATE SOLUTIONS CORP. (AZ) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 A2Z Cust2Mate Completes Acquisition of In-Store Retail Media Business Hedia ● Strategic acquisition adds an established retail media business with approximately $20 million in annual revenues, advertiser relationships and campaign execution capabilities to Cust2Mate

$AZMedAI 8/10

A2Z Reports Second Quarter 2026 Revenue of $5.9 Million

A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) reported Q2 2026 revenue of $5.9 million, up from $1.2 million, with Smart Cart revenue of $4.41 million. Gross profit rose to $2.5 million and gross margin to 42.6%. Net loss was $7.3 million. The company cited a $30 million credit line with Bank Leumi and expects $25 million in H2 smart cart revenue.

$AZMedAI 8/10

Allianz enters deal to acquire UOB asset management arm

Allianz Global Investors agreed to acquire UOB Asset Management for S$555m (US$432.7m), covering UOBAM operations in eight Asian markets. UOB and AGI will also form a distribution partnership. UOB expects a pre-tax gain of about S$330m and a CET ratio lift of 14 bps, subject to regulatory approval, with closing in 2027.

$AZMedAI 8/10

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI said it licensed Alphamab’s bispecific ADC JSKN016 for solid tumors outside Greater China in a deal worth up to $2.2 billion, including $125 million upfront, up to $2.09 billion in milestones and royalties. JSKN016 targets TROP2 and HER3 and is in Phase 3 for TNBC. Pathos also partnered with AstraZeneca on AZD4241, an ER-targeting PROTAC in preclinical testing for HR-positive, HER2-negative breast cancer.